PDS Biotech amends USD 6 million promissory note with YA II PN Ltd

• PDS Biotechnology amended a $6 million Promissory Note with YA II PN on Aug. 31, 2026.
• Revision tightens cash sweeps tied to the at-the-market program via weekly remittance notices, with payment due within one business day.
• New term requires 100% of net cash proceeds from any equity or equity-linked financing outside the ATM to redeem the note within five business days.
• Nasdaq listing deficiency cure period under the note extended to 180 days from 75 days.
• Amendment takes effect once the Sept. 14, 2026 installment under the note is paid in full.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-035809), on September 04, 2026, and is solely responsible for the information contained therein.